FDA flags unapproved salt forms of semaglutide

FDA has repeatedly distinguished semaglutide base — the active ingredient in the approved products — from salt forms such as semaglutide sodium and semaglutide acetate, and has linked the salt forms to safety concerns.

This is one of the few technical details in this category that a patient can and should check. A legitimate compounded preparation uses the base peptide. A vial labelled with a salt form is not the same product as the one in the trials.

Ask any programme, in writing, which form its pharmacy compounds from. A programme that answers specifically is behaving well; one that cannot answer the question has told you something about how closely it supervises its supply chain.

Also ask for a certificate of analysis for the lot you are dispensed. Good operations produce them on request.

How to read a consumer alert story in this market

An alert here requires a documented pattern rather than isolated dissatisfaction, and it is never an allegation of fraud. What we can evidence is what people report and what regulators publish; what we cannot evidence, we do not print.

The recurring shape is money leaving before medicine arrives, and support becoming unreachable at exactly that point. That is a clinical problem as well as a commercial one, because an interrupted supply means missed doses.

What this does not change

The prescription requirement, the licensing framework behind a dispensing pharmacy, and the clinical review that should sit in front of any prescription. Those are stable and none of the developments we track has altered them.

It also does not change the arithmetic of choosing a programme: price the dose you expect to hold, add every recurring fee, and verify the pharmacy. The cheapest verified route we track is NexLife at $145 a month all-in at a maintenance dose, about $1,740 for a first year.

Where a development does move those figures, the tables regenerate from the dataset on the next build rather than being edited by hand.

When urgency is the product

Regulatory and market news is routinely used as a sales device. A programme citing a rule change to push you into a twelve-month prepayment is using a real fact to manufacture a deadline that does not apply to you.

The test is simple: does the development change what you can lawfully be prescribed this month? Almost never. Does it change what you should pay? Sometimes. Does it require you to decide today? Essentially never — and a programme insisting otherwise has told you how it treats patients under commercial pressure.

Putting consumer alert in proportion

It is one input into a decision with three parts: what you pay at the dose you hold, who makes what you inject, and what happens if you stop. Weighting one to the exclusion of the others is how people end up on a cheap programme they abandon in month nine.

The frame: 20 programmes publish a capturable price, spanning $145 to $324 a month all-in at a 2.4 mg maintenance dose. 4 charge a mandatory recurring fee. 6 name the dispensing pharmacy before purchase.

What good looks like

A figure at a named dose, the pharmacy named, cancellation terms published before payment, and a plain statement that a compounded preparation is not FDA-approved. Four things, all cheap to publish, and a minority does all four.

The cheapest verified route sits at $145 a month, which establishes that disclosure and low price are not in tension.

What to ask before you pay

Five questions, all answerable in a short email, all before a medical history changes hands: the total at a maintenance dose including every fee; which pharmacy fills it; whether the prescriber is licensed in your state; the notice period to cancel and what is refundable; and which form of the active ingredient the pharmacy compounds from.

None requires clinical training to evaluate. The speed and specificity of the reply tells you how the operation is run, and it arrives before your money does.

Reading this alongside the rest of the site

Pricing pages isolate one component. Provider reviews carry the whole record for one programme. Comparisons run two side by side at every dose. The rankings sort the same dataset on different questions. None is the whole picture and none is meant to be.

If you read one other page, make it how to verify a pharmacy. Price is the easiest thing to compare and rarely the thing that goes wrong.

What we would need to change our mind

A programme publishing a figure at a dose tier currently blank. A named dispensing pharmacy with a checkable licence. A pricing model changing in either direction. A regulatory action. Or a correction from a reader with a source we can open.

All five are logged with the date they landed, on the change log and in the dataset. Prices here were captured 2026-08-05.

What this site will not do

Publish an estimated price for a programme that does not publish one. Rank a programme higher because it pays. Present a compounded preparation as equivalent to an approved product. Or carry a figure without the date it was captured.

Those four rules cost us pages, rankings and revenue, and they are the only reason a reader has to prefer this to a round-up assembled in an afternoon. A price without its date is not a fact, and a comparison built from undated prices is not a comparison.

Who this site is not for

Anyone with coverage under a documented indication, who should use it rather than read a cash comparison. Anyone looking for a source without a prescription, which this site will not help with. And anyone wanting a single confident recommendation, because the honest answer depends on your dose, your coverage and your tolerance for commitment.

If you want the short version anyway: price the dose you will hold, add every fee, verify the pharmacy, and avoid long prepaid terms until you have tolerated a maintenance dose for a cycle.

What this changes for what you pay

Most developments in this category move one of three things: the price of the branded product, which programmes are operating, or what may lawfully be compounded. Very few change the prescription requirement, the pharmacy licensing framework or the clinical review behind a prescription.

The cheapest verified compounded route we track currently sits at $145 a month all-in at a 2.4 mg maintenance dose, about $1,740 for a first year. Where a development moves that figure, our tables move with it on the next build.

How to verify this yourself

Regulatory claims should be checked against the agency rather than against coverage of the agency. FDA publishes warning letters searchable by company name, a shortage database, and its compounding pages. Trial claims should be checked against the registry entry rather than a press release.

Every source behind this item is linked below, and where a story is still moving we say so rather than implying it is settled.